Surely this GSK update will be released by Biota?"GSK has...

Surely this GSK update will be released by Biota?

"GSK has therefore contacted governments around the world to ascertain demand for Relenza, including those countries most affected by the virus, such as Mexico and the USA. As a result, GSK has put in place a series of measures this week to manage existing stocks of Relenza and raise production levels"

Indicates there is demand for Relenza, above the 50-60m per annum mark.

"As of 23rd April 2009, the company had fulfilled all orders received from commercial and public purchasers for Relenza. GSK currently has 6 million treatment packs of existing Relenza stock. This week, GSK prioritised orders to governments and is working with them to determine the best mechanisms for distribution of Relenza either through public or commercial routes. "

This quarters royalty should be >$10m

"GSK is also exploring alternative delivery systems for Relenza, beyond the currently approved Diskhaler device. GSK plans to discuss these alternatives with regulatory authorities shortly with the objective of agreeing a potentially expedited pathway to approval and availability "

... very interesting

"GSK plans to directly allocate a proportion of newly manufactured stock to LDCs either directly or through multi-lateral agencies. In addition, the company remains committed to engaging in voluntary license discussions with any companies willing to manufacture and supply a zanamivir product for use in developing countries."

... WHO putting the pressure on GSK to allow access for poorer countries, possibly threatened with broken patents.